Ampio Pharmaceutical (AMPE) 8.52 $AMPE
Strong On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Wed Mar 18, 9:03AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)
Market Maker Surveillance Report. AMPE, EBIX, ITG, AMRN, ECOM, LOCO, Winning Stocks With Lowest Price Friction For Friday, March 13th 2015
M2 - Mon Mar 16, 6:53AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5298 companies with "abnormal" market making, 2008 companies with positive Friction Factors and 4028 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ampio Pharmaceuticals Inc (NYSE:AMPE), Ebix Inc (NASDAQ:EBIX), INVESTMENT TECHNOLOGY GROUP (NYSE:ITG), Amarin Corp PLC (NASDAQ:AMRN), (NYSE:ECOM), (NASDAQ:LOCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ITG: 28.25 (+0.10), ECOM: 11.38 (-0.06), AMRN: 2.52 (-0.03), LOCO: 27.00 (+1.11), EBIX: 30.19 (-1.06), AMPE: 8.52 (+0.08)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)
Premarket Gainers / Losers as of 9:20 am
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
CBI: 45.29 (+0.86), SSH: 4.00 (-0.08), CRIS: 2.73 (-0.13), PERI: 3.30 (+0.06), PBR.A: 5.67 (+0.28), RUBI: 18.18 (-0.21), BNFT: 39.22 (+0.92), BIOC: 2.45 (-0.12), AMPE: 8.52 (+0.08), NBG: 1.34 (+0.14), WGBS: 4.17 (+0.06), HPQ: 33.28 (+0.44), WBAI: 11.06 (+1.08), PBR: 5.59 (+0.33), SMSI: 1.32 (+0.03), LC: 20.09 (+0.17), CLRX: 1.07 (-0.05), CHK: 13.61 (+0.11), BSFT: 35.20 (+0.38), SFXE: 4.30 (+0.14), ATRS: 2.67 (-0.02), CHS: 18.24 (+0.11), CAPN: 5.37 (-0.33), SLCA: 31.49 (+1.66)
Ampio Too Busy to Tell Investors Results of Eye Drug Study
at The Street - Wed Feb 25, 6:55AM CST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
AMPE: 8.52 (+0.08)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 49.53 (+1.33), THRXV: 28.00 (+7.07), AMPE: 8.52 (+0.08), CEMP: 39.77 (-1.15), THRX: 17.03 (-0.94), XNPT: 8.38 (-0.08)
Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 8.52 (+0.08), ACOR: 34.74 (-0.39), ALKS: 67.20 (-0.86), ALXA: 2.13 (-0.04), AGN: 240.22 (+2.88), ALDX: 10.80 (+0.20), ALIM: 5.12 (+0.08), AMAG: 58.20 (-0.04), FOLD: 11.61 (-0.85)
Ampio Pharmaceuticals (AMPE) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:04AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
AMPE: 8.52 (+0.08)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
Alpha Exposure - Seeking Alpha - Tue Jan 27, 12:52PM CST
We believe Ampio Pharmaceuticals (NYSEMKT: AMPE ) is a stock promotion that is run by management with an alleged history of fraud and is aggressively promoting itself in preparation for a secondary. AMPE is quickly running out of cash and needs to...
UNXL: 6.55 (-0.33), AMPE: 8.52 (+0.08)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), ANIK: 40.84 (-0.63), CBYL: ()
Ampio Pharmaceuticals (AMPE) Strong On High Relative Volume Today
at The Street - Tue Jan 27, 9:02AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)
Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
PR Newswire - Thu Jan 22, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
AMPE: 8.52 (+0.08)
Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 8:39AM CST
Ampio Pharmaceuticals, Inc. (AMPE) was a big mover last session, as the company saw its shares rise over 14% on the day.
AMPE: 8.52 (+0.08), IG: 9.32 (+0.65)
Ampio Pharma up after Vyrix presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 2:45PM CST
AMPE: 8.52 (+0.08)
Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Thu Jan 08, 6:57AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)
Luoxis to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)
Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014
PR Newswire - Thu Dec 04, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11th, 2014. The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.
AMPE: 8.52 (+0.08)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial
PR Newswire - Mon Dec 01, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.
AMPE: 8.52 (+0.08)
Strong On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Wed Mar 18, 9:03AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)
Market Maker Surveillance Report. AMPE, EBIX, ITG, AMRN, ECOM, LOCO, Winning Stocks With Lowest Price Friction For Friday, March 13th 2015
M2 - Mon Mar 16, 6:53AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5298 companies with "abnormal" market making, 2008 companies with positive Friction Factors and 4028 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ampio Pharmaceuticals Inc (NYSE:AMPE), Ebix Inc (NASDAQ:EBIX), INVESTMENT TECHNOLOGY GROUP (NYSE:ITG), Amarin Corp PLC (NASDAQ:AMRN), (NYSE:ECOM), (NASDAQ:LOCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ITG: 28.25 (+0.10), ECOM: 11.38 (-0.06), AMRN: 2.52 (-0.03), LOCO: 27.00 (+1.11), EBIX: 30.19 (-1.06), AMPE: 8.52 (+0.08)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)
Premarket Gainers / Losers as of 9:20 am
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST
CBI: 45.29 (+0.86), SSH: 4.00 (-0.08), CRIS: 2.73 (-0.13), PERI: 3.30 (+0.06), PBR.A: 5.67 (+0.28), RUBI: 18.18 (-0.21), BNFT: 39.22 (+0.92), BIOC: 2.45 (-0.12), AMPE: 8.52 (+0.08), NBG: 1.34 (+0.14), WGBS: 4.17 (+0.06), HPQ: 33.28 (+0.44), WBAI: 11.06 (+1.08), PBR: 5.59 (+0.33), SMSI: 1.32 (+0.03), LC: 20.09 (+0.17), CLRX: 1.07 (-0.05), CHK: 13.61 (+0.11), BSFT: 35.20 (+0.38), SFXE: 4.30 (+0.14), ATRS: 2.67 (-0.02), CHS: 18.24 (+0.11), CAPN: 5.37 (-0.33), SLCA: 31.49 (+1.66)
Ampio Too Busy to Tell Investors Results of Eye Drug Study
at The Street - Wed Feb 25, 6:55AM CST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
AMPE: 8.52 (+0.08)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 49.53 (+1.33), THRXV: 28.00 (+7.07), AMPE: 8.52 (+0.08), CEMP: 39.77 (-1.15), THRX: 17.03 (-0.94), XNPT: 8.38 (-0.08)
Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 8.52 (+0.08), ACOR: 34.74 (-0.39), ALKS: 67.20 (-0.86), ALXA: 2.13 (-0.04), AGN: 240.22 (+2.88), ALDX: 10.80 (+0.20), ALIM: 5.12 (+0.08), AMAG: 58.20 (-0.04), FOLD: 11.61 (-0.85)
Ampio Pharmaceuticals (AMPE) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:04AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
AMPE: 8.52 (+0.08)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
Alpha Exposure - Seeking Alpha - Tue Jan 27, 12:52PM CST
We believe Ampio Pharmaceuticals (NYSEMKT: AMPE ) is a stock promotion that is run by management with an alleged history of fraud and is aggressively promoting itself in preparation for a secondary. AMPE is quickly running out of cash and needs to...
UNXL: 6.55 (-0.33), AMPE: 8.52 (+0.08)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), ANIK: 40.84 (-0.63), CBYL: ()
Ampio Pharmaceuticals (AMPE) Strong On High Relative Volume Today
at The Street - Tue Jan 27, 9:02AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)
Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
PR Newswire - Thu Jan 22, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
AMPE: 8.52 (+0.08)
Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 8:39AM CST
Ampio Pharmaceuticals, Inc. (AMPE) was a big mover last session, as the company saw its shares rise over 14% on the day.
AMPE: 8.52 (+0.08), IG: 9.32 (+0.65)
Ampio Pharma up after Vyrix presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 2:45PM CST
AMPE: 8.52 (+0.08)
Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Thu Jan 08, 6:57AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)
Luoxis to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)
Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014
PR Newswire - Thu Dec 04, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11th, 2014. The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.
AMPE: 8.52 (+0.08)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial
PR Newswire - Mon Dec 01, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.
AMPE: 8.52 (+0.08)
